Syngene International Limited
Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform (CRAMS). Total research & manufacturing infrastructure for the company is spread across 1.9 million square feet across locations.
What Syngene files
- Investor Meet96
- Others83
- Important38
- Updates17
- Board Meeting13
- PPTs10
Syngene's Q1 FY27 revenue dropped 16% to 736 Cr, with EBITDA down 56% to 91 Cr, impacted by lower biologics client offtake and forex loss. The company expects H1 degrowth, H2 improvement, aiming for single-digit revenue degrowth for the full year. Kiran Mazumdar-Shaw is the new Executive Chairperson, focusing on...
Syngene International appoints Siddharth Mittal as new MD & CEO. Coming from Biocon, Mittal plans to sharpen commercial edge, strengthen delivery, and boost execution to restore growth and unlock value for investors.
Syngene proposed a final dividend of Re. 1.25 per share for FY2025-26, subject to shareholder approval. Tax will be deducted at source. Shareholders should ensure updated details are on record for proper tax calculation on the dividend payment.
Syngene International urges shareholders to claim unclaimed dividends (FY18-19 onwards) and update KYC by August 21, 2026. Failing this, dividends and corresponding shares will transfer to IEPF. Act swiftly to avoid potential loss of access.
Syngene International's board approved a key leadership change. Peter Bains will step down as MD & CEO, with Siddharth Mittal appointed as his successor, marking a significant management transition.